Shilpa Medicare Ltd

Shilpa Medicare Ltd

Shilpa Medicare Ltd has received Europe GMP approval for its Unit 4 in Jadcherla, Telangana. The unit was inspected by AGES, Austria from July 27 to 30, 2026, and was issued GMP certification. The unit is engaged in manufacturing, testing, and distribution of sterile injections and non-sterile tablets and capsules in Europe and other global markets.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026, as required by the National Stock Exchange of India Ltd and BSE Limited.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has received a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or significant stake acquisition by Ramakant Innani and others.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced the closure of its trading window for all designated persons and their relatives, effective from 01 October 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended 30 September 2026.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has been assigned an Environmental, Social and Governance (ESG) score of 'Crisil ESG 59' by CRISIL ESG Ratings, based on disclosures for fiscal 2026 and other publicly available data.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced an investors/analysts meet on 28 September 2026 in Mumbai, where the company officials will meet with certain investors/analysts in a 1x1 and group format. No unpublished price sensitive information will be shared during the meeting.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced that the USFDA conducted a surveillance inspection at its Analytical Services Division in Hyderabad, which concluded with one procedural observation. The company will address the observation and respond within the stipulated timeline.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has submitted the scrutinizer's report on the 39th AGM resolutions along with the voting results.

Shilpa Medicare Ltd

Shilpa Medicare Ltd dispatches letters to shareholders whose e-mail addresses are not registered with the company, providing web-links for the Annual Report and Notice of the 39th Annual General Meeting.

Shilpa Medicare Ltd

Shilpa Medicare Ltd initiates voluntary recall of 27,923 vials of chemotherapy drug in the US due to atypical discoloration, classified as a Class II recall by the US FDA.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced a dividend of Re. 0.60/- per Equity Share for the financial year ended March 31, 2026. The record date for determining entitlement of members to receive the Final dividend is Friday, 4 September, 2026. The dividend, if approved by the Shareholders, will be paid within the prescribed period of 30 days from the date of the forthcoming Annual General Meeting scheduled to be held on Friday, 11 September, 2026.

Shilpa Medicare Ltd

Shilpa Medicare Ltd announced the newspaper publication of the 39th Annual General Meeting notice, e-voting, and other information to shareholders. The notice was published in Business Line and Suddi Moola newspapers on August 14, 2026. The company has dispatched the Annual Report 2025-26 electronically.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced its Q1FY27 earnings conference call transcript, highlighting its strong performance and future growth prospects. The company has reduced its net debt-to-EBITDA ratio to 1.3x and achieved a double-digit ROCE. It has also made significant investments in biologics, CDMO, and novel drug delivery, with plans to monetize these assets in the future.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced its Q1FY27 earnings, with revenue increasing by 43% YoY to INR 469 crores and EBITDA growing by 42% YoY to INR 139 crores. The company has also reported its highest quarterly revenue and EBITDA ever, with a robust margin of 30%. The management commentary highlights the company's strong operating discipline and strategic direction, with a focus on building a differentiated and integrated organization.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced the record date for determining shareholders entitled for payment of final dividend for FY 2025-26, if declared at the 39th AGM, as Friday, 4th September 2026.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's revenue from operations was Rs. 18,904 lakhs, with net sales/income from operations at Rs. 16,592 lakhs. Other income was Rs. 956 lakhs. The company has also announced the appointment of a new Whole-time Director, Mr. Sharath Reddy Kalakota, and the payment of remuneration to a Non-Executive Director. Additionally, the company has informed about a proposed strategic long-term equity partnership with Gate2Brain, and the details of the 39th Annual General Meeting (AGM) have been announced.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 18,904 lakhs and net sales/income from operations at Rs. 16,592 lakhs. The company has also announced the appointment of a new whole-time director, Mr. Sharath Reddy Kalakota, and the payment of remuneration to a non-executive director. Additionally, the company has informed about a proposed strategic long-term equity partnership with Gate2Brain and the schedule for the 39th AGM.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has appointed Dr. Uday N. Harle as the Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly owned subsidiary, effective August 3, 2026.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has scheduled an investor conference call for Q1-FY27 earnings on August 5, 2026, at 4:00 PM IST.

Shilpa Medicare Ltd

Shilpa Medicare Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 05/08/2026 to consider and approve unaudited financial results for the quarter ended 30 June, 2026.